Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.

Antimicrobial Agents and Chemotherapy
R GarraffoP Lapalus

Abstract

The pharmacokinetics and serum killing curves of amikacin, which was administered by a 30-minute intravenous infusion of single doses of 7.5 mg/kg and then 15 mg/kg, were investigated in six healthy volunteers who received the two doses in a crossover study with a washout period of 20 days. The serum killing curves were determined for four bacterial species: Escherichia coli, Serratia marcescens, Enterobacter cloacae, and Pseudomonas aeruginosa. All strains were serum resistant, and the bactericidal activity was analyzed by separating the early phase (first 5 h) and the late phase (24 h) of the killing curve. For the early phase, the bactericidal activity was evaluated by correlating an index of surviving bacteria with amikacin concentrations. This methodology allowed determination of two parameters: the maximal effective concentration and the lowest effective concentration. For the late phase, the threshold values separating bacteriostatic and bactericidal activities were lower than 10 mg/liter for each strain. The concentration dependence of amikacin bactericidal activity was confirmed for Escherichia coli and Enterobacter cloacae and, to a lesser extent, for Serratia marcescens and Pseudomonas aeruginosa. Correlation of thes...Continue Reading

References

Oct 18, 1976·JAMA : the Journal of the American Medical Association·T A Stamey, J Bragonje
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
May 1, 1986·The Journal of Pediatrics·B Vogelman, W A Craig
Jan 1, 1985·The Journal of Antimicrobial Chemotherapy·A U Gerber, C Feller-Segessenmann
Feb 1, 1974·The Journal of Infectious Diseases·J KlasterskyD Weerts
Nov 1, 1983·Antimicrobial Agents and Chemotherapy·T A DrakeM A Sande

❮ Previous
Next ❯

Citations

Aug 1, 1992·Journal of Clinical Pharmacology·C Carbón
Nov 29, 2011·International Journal of Otolaryngology·M E HuthA G Cheng
Jan 16, 2002·American Journal of Respiratory and Critical Care Medicine·Ivan GoldsteinJean-Jacques Rouby
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Ivan GoldsteinJean-Jacques Rouby
Sep 15, 2007·Clinical Pharmacokinetics·Duangchit PanomvanaDanabhand Phiboonbanakit
Apr 15, 2011·International Journal of Antimicrobial Agents·Fabio Silvio TacconeFrédérique Jacobs
Feb 1, 1996·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Laurence BelfayolFrancise Fauvelle
Jul 24, 2013·Burns : Journal of the International Society for Burn Injuries·Catherine M T SherwinRichard Kagan
Aug 29, 2014·Journal of Burn Care & Research : Official Publication of the American Burn Association·Jessica K OrtwineJanie Faris
Jun 22, 2016·Clinical Pharmacokinetics·Amélie MarsotOlivier Blin
Sep 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Federico Pea
Sep 1, 1995·The Annals of Pharmacotherapy·R D ColucciE Radwanski
Sep 19, 2019·Expert Opinion on Drug Delivery·Ludger M Ickenstein, Patrick Garidel
Nov 30, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marieke G G SturkenboomJan-Willem C Alffenaar
Sep 18, 2020·International Journal of Antimicrobial Agents·Suzanne L ParkerJason A Roberts
Feb 12, 2020·Antimicrobial Agents and Chemotherapy·Norma A Aréchiga-AlvaradoSilvia Romano-Moreno
Jan 16, 2021·Clinical Pharmacokinetics·Mehdi El HassaniAmélie Marsot
Feb 18, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Christopher M RubinoKevin L Winthrop
May 6, 2021·Antibiotics·Alexandre DuongAmélie Marsot

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.